Klas G. Wiman

18.2k total citations · 3 hit papers
179 papers, 14.1k citations indexed

About

Klas G. Wiman is a scholar working on Oncology, Molecular Biology and Biotechnology. According to data from OpenAlex, Klas G. Wiman has authored 179 papers receiving a total of 14.1k indexed citations (citations by other indexed papers that have themselves been cited), including 130 papers in Oncology, 127 papers in Molecular Biology and 28 papers in Biotechnology. Recurrent topics in Klas G. Wiman's work include Cancer-related Molecular Pathways (120 papers), Epigenetics and DNA Methylation (32 papers) and Ubiquitin and proteasome pathways (28 papers). Klas G. Wiman is often cited by papers focused on Cancer-related Molecular Pathways (120 papers), Epigenetics and DNA Methylation (32 papers) and Ubiquitin and proteasome pathways (28 papers). Klas G. Wiman collaborates with scholars based in Sweden, France and United States. Klas G. Wiman's co-authors include Vladimir J.N. Bykov, Galina Selivanova, Thierry Soussi, László Székely, Jan Bergman, Sofi Eriksson, Julie Bianchi, Lars Rask, Kristinn P. Magnússon and Pierre Hainaut and has published in prestigious journals such as Nature, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

Klas G. Wiman

178 papers receiving 13.6k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound

2002 840 citations Vladimir J.N. Bykov, Klas G. Wiman et al. profile →
Targeting mutant p53 for efficient cancer therapy

2017 694 citations Vladimir J.N. Bykov, Sofi Eriksson et al. profile →
Activation of a translocated human c-myc gene by an enhancer in the immunoglobulin heavy-chain locus

1984 234 citations Adrian Hayday, Klas G. Wiman et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Klas G. Wiman Sweden	67	9.3k	7.0k	2.3k	2.0k	1.6k	179	14.1k
Gerard P. Zambetti United States	58	10.6k 1.1×	8.0k 1.1×	3.2k 1.4×	1.2k 0.6×	1.7k 1.1×	133	15.7k
Thierry Soussi France	62	7.5k 0.8×	7.9k 1.1×	3.2k 1.4×	1.2k 0.6×	1.7k 1.1×	174	13.1k
Roderick L. Beijersbergen Netherlands	48	10.9k 1.2×	5.1k 0.7×	2.2k 1.0×	1.5k 0.7×	976 0.6×	117	15.7k
Maureen E. Murphy United States	54	8.4k 0.9×	5.4k 0.8×	2.4k 1.0×	2.2k 1.1×	868 0.5×	143	12.8k
Ygal Haupt Australia	48	9.0k 1.0×	7.1k 1.0×	2.2k 0.9×	898 0.5×	1.5k 1.0×	111	12.4k
Varda Rotter Israel	77	11.9k 1.3×	10.2k 1.5×	4.1k 1.8×	1.4k 0.7×	2.5k 1.6×	270	18.4k
Stephen N. Jones United States	50	10.6k 1.1×	5.9k 0.8×	2.4k 1.0×	910 0.5×	1.1k 0.7×	114	13.2k
Øystein Fodstad Norway	68	8.1k 0.9×	5.6k 0.8×	4.5k 1.9×	2.6k 1.3×	1.0k 0.6×	307	14.8k
Takashi Tokino Japan	62	12.8k 1.4×	6.5k 0.9×	3.8k 1.6×	1.3k 0.6×	1.1k 0.7×	227	17.4k
Matilde Todaro Italy	53	8.1k 0.9×	9.3k 1.3×	4.1k 1.8×	3.5k 1.7×	1.0k 0.6×	137	16.4k

Countries citing papers authored by Klas G. Wiman

Since Specialization

Citations

This map shows the geographic impact of Klas G. Wiman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Klas G. Wiman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Klas G. Wiman more than expected).

Fields of papers citing papers by Klas G. Wiman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Klas G. Wiman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Klas G. Wiman. The network helps show where Klas G. Wiman may publish in the future.

Co-authorship network of co-authors of Klas G. Wiman

This figure shows the co-authorship network connecting the top 25 collaborators of Klas G. Wiman. A scholar is included among the top collaborators of Klas G. Wiman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Klas G. Wiman. Klas G. Wiman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wiman, Klas G., et al.. (2024). Therapeutic targeting of TP53 nonsense mutations in cancer. Upsala Journal of Medical Sciences. 129. e10719–e10719. 3 indexed citations

Liu, Jianping, et al.. (2023). Novel compounds that synergize with aminoglycoside G418 or eRF3 degraders for translational readthrough of nonsense mutant TP53 and PTEN. RNA Biology. 20(1). 368–383. 7 indexed citations

Bykov, Vladimir J.N., et al.. (2023). Pharmacological induction of translational readthrough of nonsense mutations in the retinoblastoma (RB1) gene. PLoS ONE. 18(11). e0292468–e0292468. 4 indexed citations

Zhang, Qiang, Bruno Baron, Tali E. Haran, et al.. (2022). Evolutionary history of the p53 family DNA-binding domain: insights from an Alvinella pompejana homolog. Cell Death and Disease. 13(3). 214–214. 14 indexed citations

Meineke, Birthe, et al.. (2022). Translational readthrough of nonsense mutant TP53 by mRNA incorporation of 5-Fluorouridine. Cell Death and Disease. 13(11). 997–997. 16 indexed citations

Ceder, Sophia, Sofi Eriksson, Ying Liang, et al.. (2021). Mutant p53-reactivating compound APR-246 synergizes with asparaginase in inducing growth suppression in acute lymphoblastic leukemia cells. Cell Death and Disease. 12(7). 709–709. 12 indexed citations

Leroy, Bernard, Isabelle Martins, Johanna Sofia Margareta Mattsson, et al.. (2020). Identification and functional characterization of new missense SNPs in the coding region of the TP53 gene. Cell Death and Differentiation. 28(5). 1477–1492. 22 indexed citations

Ceder, Sophia, Sofi Eriksson, Swati Dawar, et al.. (2020). A thiol‐bound drug reservoir enhances APR‐246‐induced mutant p53 tumor cell death. EMBO Molecular Medicine. 13(2). e10852–e10852. 29 indexed citations

Kharaziha, Pedram, Sophia Ceder, Stefanie Böhm, et al.. (2019). Functional characterization of novel germline TP53 variants in Swedish families. Clinical Genetics. 96(3). 216–225. 9 indexed citations

10.

Synnott, Naoise C., Stephen F. Madden, Vladimir J.N. Bykov, et al.. (2018). The Mutant p53-Targeting Compound APR-246 Induces ROS-Modulating Genes in Breast Cancer Cells. Translational Oncology. 11(6). 1343–1349. 27 indexed citations

11.

Zhang, Qiang, Vladimir J.N. Bykov, Klas G. Wiman, & Joanna Zawacka‐Pankau. (2018). APR-246 reactivates mutant p53 by targeting cysteines 124 and 277. Cell Death and Disease. 9(5). 439–439. 186 indexed citations

12.

Lu, Jun, Vladimir J.N. Bykov, Xiaoyuan Ren, et al.. (2018). Inhibition of the glutaredoxin and thioredoxin systems and ribonucleotide reductase by mutant p53-targeting compound APR-246. Scientific Reports. 8(1). 12671–12671. 55 indexed citations

13.

Liu, David S., Cuong Duong, Sue Haupt, et al.. (2017). Inhibiting the system xC−/glutathione axis selectively targets cancers with mutant-p53 accumulation. Nature Communications. 8(1). 14844–14844. 260 indexed citations

14.

Salamon, Dániel, Klas G. Wiman, Sonia Laı́n, et al.. (2012). p53 contributes to T cell homeostasis through the induction of pro-apoptotic SAP. Cell Cycle. 11(24). 4563–4569. 22 indexed citations

15.

Lambert, Jérémy, Ali Moshfegh, Pierre Hainaut, Klas G. Wiman, & Vladimir J.N. Bykov. (2009). Mutant p53 reactivation by PRIMA-1MET induces multiple signaling pathways converging on apoptosis. Oncogene. 29(9). 1329–1338. 85 indexed citations

16.

Uggla, Bertil, Stefan Deneberg, Sofia Bengtzén, et al.. (2009). Low p14ARF expression in de novo acute myeloid leukemia with normal karyotype is associated with poor survival. Leukemia & lymphoma. 50(9). 1512–1518. 4 indexed citations

17.

Klangby, Ulf, İsmail Okan, Kristinn P. Magnússon, et al.. (1998). p16/INK4a and p15/INK4b Gene Methylation and Absence of p16/INK4a mRNA and Protein Expression in Burkitt's Lymphoma. Blood. 91(5). 1680–1687. 74 indexed citations

18.

Bakalkin, Georgy, Galina Selivanova, Tatjana Yakovleva, et al.. (1995). p53 binds single-stranded DNA ends through the C-terminal domain and internal DNA segments via the middle domain. Nucleic Acids Research. 23(3). 362–369. 140 indexed citations

19.

Saito, Hirohisa, Adrian Hayday, Klas G. Wiman, W S Hayward, & Susumu Tonegawa. (1983). Activation of the c-myc gene by translocation: a model for translational control.. Proceedings of the National Academy of Sciences. 80(24). 7476–7480. 174 indexed citations

20.

Kvist, Sune, François Brégégère, Lars Rask, et al.. (1981). cDNA clone coding for part of a mouse H-2d major histocompatibility antigen.. Proceedings of the National Academy of Sciences. 78(5). 2772–2776. 61 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact